Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Safety and efficacy of aponermin-based chemotherapy as bridging therapy before CAR-T cell treatment in relapsed/refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

YFYanli FengYLYang LiuCLChunrui Li

Discussion

Loading...

Member takes

Overview

Retrospective cohort study shows that aponermin bridging therapy achieved 41.7% response rate in relapsed myeloma, suggesting improved CAR-T efficacy.

Key Points

  • Progression-free survival of 6.43 months noted after CAR-T treatment in 23 patients.
  • Bridging therapy using aponermin maintained favorable safety profile with minimal adverse effects.
  • Complete response observed in 7.1% of patients after bridging therapy, followed by substantial CAR-T efficacy.
  • Significant platelet elevation may reduce bleeding risk post-ponermin treatment before CAR-T infusion.

Cite This Study

Feng et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df3fhttps://doi.org/10.1182/blood-2025-2270
View Full Paper
Ask AI
Bookmark
Share